doi: 10.1056/NEJMp0912328.
Epub 2010 Jan 6.
Erythropoiesis-stimulating agents--time for a reevaluation
Affiliations
- PMID: 20054037
- DOI: 10.1056/NEJMp0912328
Item in Clipboard
Erythropoiesis-stimulating agents--time for a reevaluation
N Engl J Med.
.
No abstract available
Comment in
-
Reevaluating erythropoiesis-stimulating agents.N Engl J Med. 2010 May 6;362(18):1742; author reply 1743-4. doi: 10.1056/NEJMc1002263. N Engl J Med. 2010. PMID: 20445190 No abstract available.
-
Reevaluating erythropoiesis-stimulating agents.N Engl J Med. 2010 May 6;362(18):1742-3; author reply 1743-4. N Engl J Med. 2010. PMID: 20449880 No abstract available.
-
Reevaluating erythropoiesis-stimulating agents.N Engl J Med. 2010 May 6;362(18):1743; author reply 1743-4. N Engl J Med. 2010. PMID: 20449881 No abstract available.
-
Erythropoietin and the truths of science.J Nephrol. 2011 Sep-Oct;24(5):564-8. doi: 10.5301/JN.2010.5971. J Nephrol. 2011. PMID: 21058263
Similar articles
-
Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).Nephrol Dial Transplant. 2010 Jun;25(6):1734-7. doi: 10.1093/ndt/gfq099. Epub 2010 Mar 2. Nephrol Dial Transplant. 2010. PMID: 20200007 No abstract available.
-
Treatment of anemia in chronic kidney disease--strategies based on evidence.N Engl J Med. 2009 Nov 19;361(21):2089-90. doi: 10.1056/NEJMe0909664. Epub 2009 Oct 30. N Engl J Med. 2009. PMID: 19880845 No abstract available.
-
Darbepoetin alfa and chronic kidney disease.N Engl J Med. 2010 Feb 18;362(7):654; author reply 655. N Engl J Med. 2010. PMID: 20187260 No abstract available.
-
Emerging drugs for treatment of anemia of chronic kidney disease.Expert Opin Emerg Drugs. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Epub 2013 Sep 16. Expert Opin Emerg Drugs. 2013. PMID: 24033253 Review.
-
Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.Expert Opin Drug Saf. 2009 Mar;8(2):145-53. doi: 10.1517/14740330902793031. Expert Opin Drug Saf. 2009. PMID: 19309243 Review.
Cited by
-
Reports of increased mortality and GH: will this affect current clinical practice?J Clin Endocrinol Metab. 2012 Feb;97(2):380-3. doi: 10.1210/jc.2011-3363. J Clin Endocrinol Metab. 2012. PMID: 22312091 Free PMC article. No abstract available.
-
Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?Nat Rev Nephrol. 2010 Oct;6(10):566-8. doi: 10.1038/nrneph.2010.115. Nat Rev Nephrol. 2010. PMID: 20871637 No abstract available.
-
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.Adv Ther. 2019 Jun;36(6):1438-1454. doi: 10.1007/s12325-019-00943-4. Epub 2019 Apr 5. Adv Ther. 2019. PMID: 30953333 Free PMC article. Clinical Trial.
-
Clinical Application Effects of Different Preoperative Blood Management Schemes in Older Patients with Delayed Intertrochanteric Fracture Surgery.Clin Interv Aging. 2022 May 20;17:825-835. doi: 10.2147/CIA.S362020. eCollection 2022. Clin Interv Aging. 2022. PMID: 35620020 Free PMC article.
-
rHuEPO hyporesponsiveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients.ScientificWorldJournal. 2013 Sep 30;2013:792698. doi: 10.1155/2013/792698. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24198729 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
